Abstract
Somatization may contribute to persistent symptoms after mild traumatic brain injury (mTBI). In two independently-recruited study samples, we characterized the extent to which symptoms atypical of mTBI but typical for somatoform disorders (e.g., gastrointestinal upset, joint pain) were present in adult patients with prolonged recovery following mTBI. The first sample was cross-sectional and consisted of mTBI patients recruited from the community who reported ongoing symptoms attributable to a previous mTBI (n = 16) along with a healthy control group (n = 15). The second sample consisted of patients with mTBI prospectively recruited from a Level 1 trauma center who had either good recovery (GOSE = 8; n = 33) or poor recovery (GOSE < 8; n = 29). In all participants, we evaluated atypical somatic symptoms using the Patient Health Questionnaire-15 and typical post-concussion symptoms with the Rivermead Post-Concussion Symptom Questionnaire. Participants with poor recovery from mTBI had significantly higher 'atypical' somatic symptoms as compared to the healthy control group in Sample 1 (b = 4.308, p = 9.43E-5) and to mTBI patients with good recovery in Sample 2 (b = 3.287, p = 6.83E-04). As would be expected, participants with poor outcome in Sample 2 had a higher burden of typical rather than atypical symptoms (t(28) = 3.675, p = 9.97E-04, d = 0.94). However, participants with poor recovery still reported atypical somatic symptoms that were significantly higher (1.4 standard deviations, on average) than those with good recovery. Our results suggest that although 'typical' post-concussion symptoms predominate after mTBI, a broad range of somatic symptoms also frequently accompanies mTBI, and that somatization may represent an important, modifiable factor in mTBI recovery.
Competing Interest Statement
Dr. Panenka is the founder and CEO of Translational Life Sciences, an early stage biotechnology company. He is also on the scientific advisory board of Medipure Pharmaceuticals and Vitality Biopharma, and in the past has been on the board of directors for Abbatis bioceuticals and on the advisory board of Vinergy Resources. All of these companies are early stage biotechnology enterprises with no relation to brain injury. The other authors have no competing financial interests.
Funding Statement
Funding for this study was provided by the UBC Neuropsychiatry program research fund, Brain Canada, and Genome BC.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
Data from this study may be shared upon reasonable request.
